Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C - PubMed (original) (raw)
Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C
E Orito et al. J Med Virol. 1994 Dec.
Abstract
Serum hepatitis C virus (HCV) RNA level has been shown to be a good predictor of subsequent response to interferon-alpha (IFN) therapy in US patients in whom genotype 1a/1b are both predominant. To determine whether serum HCV RNA level is a predictor of subsequent response to IFN in Japanese patients or not, appropriately collected pre-IFN therapy serum samples from 35 Japanese patients with chronic HCV infection were studied. Serum HCV RNA level and HCV genotype were determined and correlated with the subsequent response to IFN. Response to IFN was defined by serum alanine transaminase level: complete and sustained response (n = 15), complete response followed by relapse (n = 10), and no response (n = 10). Patients with complete and sustained response had lower pre-IFN serum HCV RNA level (median: RT-PCR+, bDNA-) compared to the complete response to relapse group (median: 5.25 x 10(6) genome equivalent/ml [eq/ml], P < 0.001) and the no response group (median: 10.63 x 10(6) eq/ml, P < 0.001). Seven (46.7%) of the complete and sustained response patients had HCV genotype 2a and three patients had a mixture of genotypes 1b and 2a. In contrast, all 10 patients in the complete response to relapse group had genotype 1b whereas 8 of 10 patients in the non-response group had genotype 1b and 2 had genotype 2b. The patients with HCV genotype 2a had lower serum HCV RNA level than those with 1b (P = 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
Mizokami M, Orito E, Gibo Y, Suzuki K, Ohba K, Ohno T, Lau JY. Mizokami M, et al. Liver. 1996 Feb;16(1):23-7. doi: 10.1111/j.1600-0676.1996.tb00699.x. Liver. 1996. PMID: 8868074 - Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sönnerborg A, Wahl M, Wejstål R, Widell A, Norkrans G. Weiland O, et al. Scand J Infect Dis. 1995;27(5):319-24. Scand J Infect Dis. 1995. PMID: 8588128 Clinical Trial. - Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection.
Davis GL, Lau JY. Davis GL, et al. J Hepatol. 1995;22(1 Suppl):110-4. J Hepatol. 1995. PMID: 7602061 Review. - Host and viral features in chronic HCV infection: relevance to interferon responsiveness.
Craxì A, Magrin S, Fabiano C, Linea C, Almasio P. Craxì A, et al. Res Virol. 1995 Jul-Aug;146(4):273-8. doi: 10.1016/0923-2516(96)80571-1. Res Virol. 1995. PMID: 8539489 Review.
Cited by
- Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.
Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, Sánchez-Pescador R. Detmer J, et al. J Clin Microbiol. 1996 Apr;34(4):901-7. doi: 10.1128/jcm.34.4.901-907.1996. J Clin Microbiol. 1996. PMID: 8815105 Free PMC article. - Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes.
Orito E, Mizokami M, Tanaka T, Lau JY, Suzuki K, Yamauchi M, Ohta Y, Hasegawa A, Tanaka S, Kohara M. Orito E, et al. Gut. 1996 Dec;39(6):876-80. doi: 10.1136/gut.39.6.876. Gut. 1996. PMID: 9038674 Free PMC article. - Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation.
Mayerat C, Bürgisser P, Lavanchy D, Mantegani A, Frei PC. Mayerat C, et al. J Clin Microbiol. 1996 Nov;34(11):2702-6. doi: 10.1128/jcm.34.11.2702-2706.1996. J Clin Microbiol. 1996. PMID: 8897168 Free PMC article. - Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2.
Suzuki H, Sato K, Takagi H, Kanda D, Sohara N, Kakizaki S, Nakajima H, Otsuka T, Nagamine T, Mori M. Suzuki H, et al. World J Gastroenterol. 2006 Feb 14;12(6):945-50. doi: 10.3748/wjg.v12.i6.945. World J Gastroenterol. 2006. PMID: 16521225 Free PMC article. Clinical Trial. - [Characteristics of the hepatitis C virus and viral predictors of therapeutic response].
Ambrosch A, König W. Ambrosch A, et al. Med Klin (Munich). 1999 Nov 15;94(11):626-32. doi: 10.1007/BF03045003. Med Klin (Munich). 1999. PMID: 10603734 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical